tiprankstipranks
Denali Therapeutics (DNLI)
NASDAQ:DNLI
Holding DNLI?
Track your performance easily

Denali Therapeutics (DNLI) Ownership - Who Owns Denali Therapeutics?

625 Followers

Denali Therapeutics (DNLI) Ownership Overview

9.11%32.30%31.66%14.71%12.23%
31.66% Other Institutional Investors
14.71% ETFs
12.23% Public Companies and
Individual Investors
The ownership structure of Denali Therapeutics (DNLI) stock is a mix of institutional, retail, and individual investors. Approximately 78.66% of the company’s stock is owned by Institutional Investors, 9.11% is owned by Insiders, and 12.23% is owned by Public Companies and Individual Investors.
The ownership structure of Denali Therapeutics (DNLI) stock is a mix of institutional, retail, and individual investors. Approximately 63.96% of the company’s stock is owned by Institutional Investors, 9.11% is owned by Insiders, and 14.71% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Aug 22, 2024
xxxxxxxxxxxxx
$58357
Aug 22, 2024
Alexander O. Schuth
Cofo And Secretary
xxxxxxxxxxxxx
$58357
Aug 22, 2024
Ryan J. Watts
President & Ceo,director
xxxxxxxxxxxxx
$53765
Aug 22, 2024
xxxxxxxxxxxxx
$41085

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Sep 30, 2024
xxxxxxxxxxxxx
$342714
Sep 30, 2024
xxxxxxxxxxxxx
$15943752

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
10,452,935Institution7.26%224,215,456
9,358,249Institution6.50%200,734,441
8,797,384Institution6.11%188,703,887
6,455,547Institution4.49%138,471,483
5,750,882Insider4.20%123,356,419
5,978,373Institution4.15%128,236,101
3,905,970Institution2.71%83,783,057
3,731,695Institution2.59%80,044,858
2,438,411Insider1.69%52,303,916
2,117,408Insider1.47%45,418,402

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
9,358,249Institution6.50%200,734,441
8,797,384Institution6.11%188,703,887
5,978,373Institution4.15%128,236,101
3,905,970Institution2.71%83,783,057
1,638,780Institution1.14%35,151,831
1,543,042Institution1.07%33,098,251
1,415,640Institution0.98%30,365,478
1,374,416Institution0.95%29,481,223
1,141,086Institution0.79%24,476,295
1,064,733Institution0.74%22,838,523

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
3,307,955Institution2.30%85,874,512
3,575,868Institution2.48%76,702,369
2,691,768Institution1.87%69,878,297
1,842,237Institution1.28%47,824,473
1,478,850Institution1.03%38,390,946
1,199,925Institution0.83%25,786,388
810,618Institution0.56%17,387,756
566,666Institution0.39%14,710,649
651,940Institution0.45%13,984,113
597,098Institution0.41%12,831,636

FAQ

Who Owns Denali Therapeutics (DNLI)?
According to the latest TipRanks data, approximately 31.66% of the company's stock is held by institutional investors, 9.11% is held by insiders, and 12.23% is held by retail investors.
    What percentage of Denali Therapeutics (DNLI) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 31.66% of Denali Therapeutics (DNLI) stock is held by institutional investors.
      What percentage of Denali Therapeutics (DNLI) stock is held by retail investors?
      According to the latest TipRanks data, approximately 12.23% of Denali Therapeutics (DNLI) stock is held by retail investors.
        Who owns the most shares of Denali Therapeutics (DNLI)?
        Vanguard owns the most shares of Denali Therapeutics (DNLI).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis